CytRx announces the presentation of the results of the Bafetinib study at the American Academy for cancer research (AACR) annual meeting

Current article ratings:
Patients / public:healthcare Prof:
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specialized in Oncology, announced that results from a number of non-clinical studies show that its oncology drug candidate Bafetinib inhibits bone destruction in model systems is presented on April 2, 2011 at the American Academy for cancer research (AACR) 102nd Annual meeting in Orlando Florida.

Dr. James R. Berenson, medical & Scientific Director of the Institute for myeloma and bone cancer research, commented: "our research shows as recently reported, Bafetinib, significantly inhibited destruction cause the cells, the bones even in low concentrations, the devastating consequences of cancer patients such as fractures can lead", Bone pain and hypercalcemia. "I think that Bafetinib certainly ensures additional study in this area."

The abstract, with the title "the tyrosine kinase inhibitor Bafetinib (INNO-406) form inhibits absorption, formation and bone" is based on a series of preclinical studies the effect of Bafetinib on bone cells (osteoclasts) of multiple myeloma patients. Osteoclasts are derived from monocytes multi core bone resorbing cells, which play important roles in bones transformed. Earlier studies showed that Lyn and Fyn kinase negative consequences for the osteoclasts, which potentially have bone resorption. Bafetinib is an inhibitor of BCR-ABL, Fyn and Lyn kinase, that these first studies in bone resorption prompts loss and bone.

The effects of Bafetinib on form to evaluate formation and bone resorption, monocytes from multiple myeloma patients and normal subjects were inspired form osteoclasts, and at the same time were treated with Bafetinib. A parallel formation and bone resorption were treated as the same kind of cells with zoledronic acid (Zometa), an inhibitor of the form currently significantly to prevent of skeletal complications for patients with multiple myeloma, Metastatic bone disease, and osteoporosis. Bafetinib and zoledronic acid of both inhibited clear form cell formation in similar concentrations in multiple myeloma and normal monocytes. An additional in vitro study demonstrated that Bafetinib form formation by blocking the way to monocyte transformation reduces. In other experiments, Bafetinib, inhibited even at low concentrations, clear bone resorption of gas resulting from concentration dependent.

CytRx President and CEO Steven A. Kriegsman said: "we see a significant opportunity with bafetinib's ability, some of the bones involved kinases block absorption, as well as cancer cell growth." "Several types of cancer a high incidence of bone metastases, and Bafetinib may have an important therapy, either alone or in combination with other agents, to handle theses types of tumors."

CytRx currently evaluated Bafetinib in three ongoing clinical trials: ENABLE phase 2 proof-of-concept clinical study in patients with a late-stage form of leukemia known as high-risk B cell chronic lymphocytic leukemia. a pharmacokinetic study in patients with recurrent brain tumors; and the PROACT phase 2 proof-of-concept prostate cancer clinical trial in patients with advanced prostate cancer.

About Bafetinib

CytRx owns the rights to Bafetinib in all regions except Japan (formerly) known as INNO-406. Bafetinib is a potent, orally available, rationally designed, dual BCR-ABL and Lyn kinase inhibitor, was developed as a third line treatment for patients with CML and certain forms of acute myeloid leukemia (AML), the refractory or intolerant of other authorised treatment. In November 2008, CytRx announced that Bafetinib showed clinical responses in patients with CML in an international, open-label phase clinical trial reaching 1 dose in patients with CML and other leukaemia, a certain mutation called the Philadelphia chromosome (Ph +) and intolerant or resistant to Glivec ® performed and, in some cases, second-line tyrosine kinase inhibitors such as Dasatinib and Nilotinib. In April 2010, the company announced that this Bafetinib had received official notification of the Committee products (COMP) for orphan medicinal by the European Medicines Agency (EMEA), which made a favourable opinion with regard to the application for pharmaceuticals orphan drug designation for the treatment of chronic myeloid leukemia (CML). Bafetinib was also an orphan-drug status for the treatment of Philadelphia chromosome positive (Ph +) CML by the U.S. food and Drug Administration (FDA) granted.

Source:
CytRx Corporation

Drug view information on Gleevec; ZOMETA.